arrow
M

Mark R. Hazebroek

university of glasgow
H指数:30
被引数:3,426

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Health status and effects of spironolactone in people at high risk of heart failure: The Heart OMics in AGEing (HOMAGE) randomized trial

心力衰竭高风险人群的螺内酯健康状态及疗效:Heart OMics in AGEing(HOMAGE)随机试验

2026-05-010
OAAI
Left Atrial Function in Patients with Titin Cardiomyopathy

Titin心肌病患者的左心房功能

2024-01-012
OA
Phenotyping patients with ischaemic heart disease at risk of developing heart failure: an analysis of the HOMAGE trial
2023-11-083
OA
Protein Biomarkers of New-Onset Heart Failure: Insights From the Heart Omics and Ageing Cohort, the Atherosclerosis Risk in Communities Study, and the Framingham Heart Study

新发心力衰竭的蛋白质生物标志物: 来自心脏组学和衰老队列,社区动脉粥样硬化风险研究和弗雷明汉心脏研究的见解

2023-05-0112
OAAI
Genetic Architecture of Acute Myocarditis and the Overlap With Inherited Cardiomyopathy
2022-10-1177
OAAI
Interatrial Block Predicts Life-Threatening Arrhythmias in Dilated Cardiomyopathy
2022-07-195
OAAI
The association between markers of type I collagen synthesis and echocardiographic response to spironolactone in patients at risk of heart failure: findings from the HOMAGE trial

有心力衰竭风险的患者中I型胶原合成标志物与螺内酯超声心动图反应之间的关联: HOMAGE试验的发现

2022-07-0519
OAAI
Left Atrial Strain Has Superior Prognostic Value to Ventricular Function and Delayed-Enhancement in Dilated Cardiomyopathy

左心房应变对扩张型心肌病的心室功能和延迟增强具有优越的预后价值

2022-06-0154
OAAI
The Effect of Spironolactone in Patients With Obesity at Risk for Heart Failure: Proteomic Insights from the HOMAGE Trial
2022-05-012
OAAI